CCND1 and prostate cancer: In AMACR-expressing prostatic cancer cell lines, Festuccia et al. reported that trifluoroibuprofen, an AMACR inhibitor structurally analogous to ibuprofen, enabled the suppression of AMACR expression with concomitant cyclin D1 downregulation [45].